Episodes (Page 22)
✨
Potential implications of Trump's presidency for the pharma industry.
✨
CDMOs' pivotal role in pharmaceutical production and supply chains.
✨
Potential changes and political interference at the FDA under Trump.
✨
GE HealthCare's AI vision discussed at HLTH conference.
Natasha Barrow
Parminder Bhatia
✨
Lilly's DTC tirzepatide ads; Pfizer's strategy defense.
✨
UK faces challenges with Alzheimer's drug cost-effectiveness.
✨
Merck & Co. acquires Modifi.
✨
Digital therapeutics are revolutionizing treatment delivery.
✨
J&J's Tremfya performance amid Stelara decline.
✨
Insights from the European Society of Medical Oncology (ESMO).
✨
Pharma strategy to avoid Medicare price negotiations.
✨
Big pharma faces cost and complexity with cell/gene therapies.
✨
Interview with AstraZeneca's Sharon Barr on biopharma R&D.
Sharon Barr
Xu Hu
✨
Making cell and gene therapies more accessible.
✨
Exploring COPD treatment strategies.
Kenneth Chinsky
✨
Navigating Medicare price negotiations with CMS.
✨
Discussion on pediatric psoriasis treatment challenges.
Valerie Welch
✨
Neffy offers a needle-free treatment for Type 1 allergies.
✨
Alpha-synuclein misfolding linked to neurodegenerative diseases.
Russ Lebovitz
✨
Discussion on PIK3CA mutations in breast cancer.
Neil Iyengar